metricas
covid
Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica Posicionamiento de darunavir en la terapia antirretroviral
Información de la revista
Vol. 26. Núm. S10.
Darunavir
Páginas 61-62 (octubre 2008)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 26. Núm. S10.
Darunavir
Páginas 61-62 (octubre 2008)
Acceso a texto completo
Posicionamiento de darunavir en la terapia antirretroviral
Visitas
1707
Bonaventura Clotet
Unitat VIH. Fundacio IrsiCaixa. Hospital Universitàri Germans Trias i Pujol. Badalona. Barcelona. España
Este artículo ha recibido
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
B. Clotet, N. Bellos, J.M. Molina, et al.
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup análisis of data from two randomised trials.
Lancet, 369 (2007), pp. 1169-1178
[2.]
J.V. Madruga, D. Berger, M. McMurchie, et al.
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 wks in treatment-experienced HIV-infected patients in TITAN: a randomised controlled phase III trial.
[3.]
R. Ortiz, E. DeJesus, H. Khanlou, E. Voronin, J. Van Lunzen, J. Andrade-Villanueva, et al.
Efficacy and safety of darunavir/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected patients at week 48.
[4.]
J.V. Madruga, P. Cahn, B. Grinsztejn, et al.
Efficacy and safety of TMC-125 (etravirine) in treatment-experienced HIV-1 infected patients in DUET-1: 24 week results from a randomised, double blind placebo controlled trial.
[5.]
A. Lazzarin, T. Campbell, B. Clotet, et al.
Efficacy and safety of TMC-125 (etravirine) in treatment-experienced HIV-1 infected patients in DUET-2: 24 week results from a randomised, double blind placebo controlled trial.
[6.]
A. Rachlis, B. Clotet, J. Baxter, R. Murphy, E. Lefebvre.
Safety, tolerability and efficacy of Darunavir (TMC114) with low dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3.
HIV Clin Trials, 8 (2007), pp. 220-231
[7.]
S. De Meyer, I. Dierynck, E. Lathouwers, et al.
Identification of mutations predictive of a diminished response to darunavir/ritonavir: Analysis of data from treatment-experienced patients in POWER 1,2,3 and DUET-1 and 2.
European HIV drug resistance workshop, (2008),
[8.]
A.R. Sedaghat, J.B. Dinoso, L. Shen, C.O. Wilke, R.F. Siliciano.
Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle.
PNAS, 105 (2008), pp. 4832-4837
Copyright © 2008. Elsevier España S.L.. Todos los derechos reservados
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos